22.728 articles found

Therapeutic use of botulinum toxin in neurorehabilitation.

Intiso D.

J Toxicol · 2011-09-14

DOI: 10.1155/2012/802893PMID: 21941544

Parkinson disease: impulsive choice-Parkinson disease and dopaminergic therapy.

Voon V, Dalley JW.

Nat Rev Neurol · 2011-09-13

DOI: 10.1038/nrneurol.2011.139PMID: 21912409

A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients.

Stocchi F, Borgohain R, Onofrj M, Schapira AH, Bhatt M, Lucini V, Giuliani R, Anand R, Study 015 Investigators.

Mov Disord · 2011-09-12

DOI: 10.1002/mds.23954PMID: 21913224

Motor improvement with bilateral subthalamic nucleus deep brain stimulation in a patient with levodopa-responsive secondary parkinsonism.

Kotagal V, Patil PG, Chou KL.

Parkinsonism Relat Disord · 2011-09-07

DOI: 10.1016/j.parkreldis.2011.08.014PMID: 21903443

Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.

Stocchi F, Rabey JM.

Eur J Neurol · 2011-09-06

DOI: 10.1111/j.1468-1331.2011.03512.xPMID: 21895884

POST-ACUTE ELECTRICAL STIMULATION TREATMENT OF ADVERSE CEREBROVASCULAR EVENTS

LAMENSDORF ITSCHAK, DAYAN AVINOAM, ALTMAN HERNAN.

· 2011-09-01

Is rTMS an effective therapeutic strategy that can be used to treat Parkinson's disease?

Arias-Carrion O, Machado S, Paes F, Velasques B, Teixeira S, Cardenas-Morales L, Piedade R, Ribeiro P, Nardi AE.

CNS Neurol Disord Drug Targets · 2011-09-01

DOI: 10.2174/187152711797247821PMID: 21838674

GDNF family ligands: a potential future for Parkinson's disease therapy.

Mickiewicz AL, Kordower JH.

CNS Neurol Disord Drug Targets · 2011-09-01

DOI: 10.2174/187152711797247876PMID: 21838676

Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson's disease.

Cenci MA, Ohlin KE, Odin P.

CNS Neurol Disord Drug Targets · 2011-09-01

DOI: 10.2174/187152711797247885PMID: 21838677

Targeting nicotinic receptors for Parkinson's disease therapy.

Quik M, Bordia T, Huang L, Perez X.

CNS Neurol Disord Drug Targets · 2011-09-01

DOI: 10.2174/187152711797247849PMID: 21838678

Kinases as targets for Parkinson's disease: from genetics to therapy.

Vancraenenbroeck R, Lobbestael E, Maeyer MD, Baekelandt V, Taymans JM.

CNS Neurol Disord Drug Targets · 2011-09-01

DOI: 10.2174/187152711797247858PMID: 21838679

Cell replacement therapy for Parkinson's disease: how close are we to the clinic?

Ganz J, Lev N, Melamed E, Offen D.

Expert Rev Neurother · 2011-09-01

DOI: 10.1586/ern.11.74PMID: 21864078